A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity — two issues that commonly co-occur with alcohol use disorder (AUD).
The results, published in JCI Insight on April 22, 2025, suggest that the drug apremilast — a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation — could be repurposed as a dual-acting…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply